Unusual Options Activity: APA, GNRC and Others Attract Market Bets, APA V/OI Ratio Reaches 868.8

EST Jul 1st Afternoon Delivery - In the last two hours of trading, 5 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.

Futu News01:30

Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105

Jefferies analyst Andrew Tsai maintains $Intra-Cellular Therapies(ITCI.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 51.6

Futu NewsJun 26 20:31 · Ratings

Intra-Cellular Therapies(ITCI.US) Director Sells US$337.19K in Common Stock

$Intra-Cellular Therapies(ITCI.US)$ Director RIGGS RORY B sold 4,462 shares of common stock on Jun 24, 2024 at an average price of $75.57 for a total value of $337.19K.Source: Announcement What is sta

Futu NewsJun 26 06:44

UBS Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $83

UBS analyst Ashwani Verma downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target from $85 to $83.

BenzingaJun 26 00:16

UBS Downgrades Intra-Cellular Therapies(ITCI.US) to Hold Rating, Raises Target Price to $83

UBS analyst Ashwani Verma downgrades $Intra-Cellular Therapies(ITCI.US)$ to a hold rating, and adjusts the target price from $80 to $83.According to TipRanks data, the analyst has a success rate of 43

Futu NewsJun 25 22:32 · Ratings

RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $103 Price Target

RBC Capital analyst Brian Abrahams reiterates Intra-Cellular Therapies with a Outperform and maintains $103 price target.

Analyst UpgradesJun 25 22:10